Although the jury is still out on the actionability of a HER2 mutation versus HER2 overexpression or amplification in colorectal cancer, the importance of performing next-generation sequencing has become apparent with all of the data reported from pivotal phase III studies, such as BEACON CRC and POLO. Listen here . . .
We recently traveled to Miami, Florida, for a State of the Science Summit™ on Gastrointestinal Malignancies. Targeted therapy has become an important fixture in oncogene-driven cancers, particularly in BRAF V600E-mutant metastatic colorectal cancer (mCRC) and BRCA-mutant metastatic pancreatic cancer.